Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue. Issue 8 (1st June 2012)
- Record Type:
- Journal Article
- Title:
- Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue. Issue 8 (1st June 2012)
- Main Title:
- Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue
- Authors:
- Ryan, Paul
Finelli, Antonio
Lawrentschuk, Nathan
Fleshner, Neil
Sweet, Joan
Cheung, Carol
van der Kwast, Theodorus
Evans, Andrew - Abstract:
- Abstract : Aims: High intensity focused ultrasound (HIFU) is currently offered as primary treatment for patients with clinically localised prostate cancer. Data on histopathological features of post-treatment biopsies are limited. Methods: Pretreatment biopsies were identified in 45 men (age range 41–85) who received primary HIFU therapy. Post-HIFU biopsies were performed in 30 of these patients (67%) at mean 14.1 months (95% CI 11.7 to 16.5) follow-up, 22 due to rising PSA and eight as part of routine follow-up. Biopsies were examined for presence, distribution and extent of adenocarcinoma, Gleason scores, use of standard immunohistochemistry and ablative tissue changes were attributable to HIFU. Results: In post-HIFU biopsies performed for biochemical failure, 17/22 (77%) contained adenocarcinoma; 4/22 (18%) had higher post-HIFU Gleason score; 3/22 (14%) had newly recognised bilateral involvement; and 4/22 (18%) had higher percentage tissue involvement compared with pre-HIFU biopsies. Of cases without rising post-HIFU PSA, 2/8 (25%) routine follow-up biopsies contained adenocarcinoma. Stromal fibrosis was the commonest finding in non-tumour post-HIFU biopsy tissue (17/30, 57%) with coagulative necrosis occurring in fewer cases (4/30, 13%) and over a shorter follow-up interval than cases showing fibrosis (8.5 (0.2–16.8) vs 15.3 (11.5–19.1) months). Treatment effects in tumour cells precluding the assignment of Gleason scores or use of immunohistochemistry in post-HIFUAbstract : Aims: High intensity focused ultrasound (HIFU) is currently offered as primary treatment for patients with clinically localised prostate cancer. Data on histopathological features of post-treatment biopsies are limited. Methods: Pretreatment biopsies were identified in 45 men (age range 41–85) who received primary HIFU therapy. Post-HIFU biopsies were performed in 30 of these patients (67%) at mean 14.1 months (95% CI 11.7 to 16.5) follow-up, 22 due to rising PSA and eight as part of routine follow-up. Biopsies were examined for presence, distribution and extent of adenocarcinoma, Gleason scores, use of standard immunohistochemistry and ablative tissue changes were attributable to HIFU. Results: In post-HIFU biopsies performed for biochemical failure, 17/22 (77%) contained adenocarcinoma; 4/22 (18%) had higher post-HIFU Gleason score; 3/22 (14%) had newly recognised bilateral involvement; and 4/22 (18%) had higher percentage tissue involvement compared with pre-HIFU biopsies. Of cases without rising post-HIFU PSA, 2/8 (25%) routine follow-up biopsies contained adenocarcinoma. Stromal fibrosis was the commonest finding in non-tumour post-HIFU biopsy tissue (17/30, 57%) with coagulative necrosis occurring in fewer cases (4/30, 13%) and over a shorter follow-up interval than cases showing fibrosis (8.5 (0.2–16.8) vs 15.3 (11.5–19.1) months). Treatment effects in tumour cells precluding the assignment of Gleason scores or use of immunohistochemistry in post-HIFU biopsies were not identified. Conclusion: Post-HIFU biopsies are positive in more than 75% of patients with elevated or rising PSA. Stromal fibrosis is common but the tissue effects of this modality do not appear to impair pathologists' ability to detect and grade adenocarcinoma in follow-up biopsies. … (more)
- Is Part Of:
- Journal of clinical pathology. Volume 65:Issue 8(2012)
- Journal:
- Journal of clinical pathology
- Issue:
- Volume 65:Issue 8(2012)
- Issue Display:
- Volume 65, Issue 8 (2012)
- Year:
- 2012
- Volume:
- 65
- Issue:
- 8
- Issue Sort Value:
- 2012-0065-0008-0000
- Page Start:
- 729
- Page End:
- 734
- Publication Date:
- 2012-06-01
- Subjects:
- Pathology -- Periodicals
Pathology, Molecular -- Periodicals
616.0705 - Journal URLs:
- http://jcp.bmjjournals.com ↗
http://jcp.bmjjournals.com/content/by/year ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=162&action=archive ↗
http://www.bmj.com/archive ↗ - DOI:
- 10.1136/jclinpath-2011-200460 ↗
- Languages:
- English
- ISSNs:
- 0021-9746
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18156.xml